To include your compound in the COVID-19 Resource Center, submit it here.

New NIH centers to validate Alzheimer’s targets

NIH’s two new research centers will seek to bridge the Alzheimer’s target validation gap, re-build pipelines

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new research centers tasked with validating new drug targets.

NIH’s National Institute on Aging (NIA) launched the centers, dubbed Alzheimer Centers for the Discovery of New Medicines, on Tuesday, which will receive over $73 million combined over

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers